Synthetic Lethal Interactions Between EGFR and PARP Inhibition in Triple Negative Breast Cancer

被引：0
|
作者：
Nowsheen, S. [1 ]
Cooper, T. [1 ]
LoBuglio, A. F. [1 ]
Bonner, J. A. [1 ]
Yang, E. S. [1 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 84卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2012.07.457
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S176 / S177
页数：2
相关论文
共 50 条
  • [1] Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells
    Nowsheen, Somaira
    Cooper, Tiffiny
    Stanley, Jennifer A.
    Yang, Eddy S.
    PLOS ONE, 2012, 7 (10):
  • [2] Synthetic lethal interaction between EGFR and PARP inhibition
    Whitley, Alexander
    Nowsheen, Somaira
    Cooper, Tiffiny
    LoBuglio, Albert
    Bonner, James
    Yang, Eddy S.
    CANCER RESEARCH, 2012, 72
  • [3] Elucidating the synthetic lethal effect of CDK inhibition in triple negative breast cancer
    Rohrberg, J.
    Corella, A.
    Starnes, L.
    Goga, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S88 - S88
  • [4] Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
    Bajrami, Ilirjana
    Kigozi, Asha
    Van Weverwijk, Antoinette
    Brough, Rachel
    Frankum, Jessica
    Lord, Christopher J.
    Ashworth, Alan
    EMBO MOLECULAR MEDICINE, 2012, 4 (10) : 1087 - 1096
  • [5] Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
    Fleury, Hubert
    Malaquin, Nicolas
    Tu, Veronique
    Gilbert, Sophie
    Martinez, Aurelie
    Olivier, Marc-Alexandre
    Sauriol, Alexandre
    Communal, Laudine
    Leclerc-Desaulniers, Kim
    Carmona, Euridice
    Provencher, Diane
    Mes-Masson, Anne-Marie
    Rodier, Francis
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [6] Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
    Shu, Shaokun
    Wu, Hua-Jun
    Ge, Jennifer Y.
    Zeid, Rhamy
    Harris, Isaac S.
    Jovanovic, Bojana
    Murphy, Katherine
    Wang, Binbin
    Qiu, Xintao
    Endress, Jennifer E.
    Reyes, Jaime
    Lim, Klothilda
    Font-Tello, Alba
    Syamala, Sudeepa
    Xiao, Tengfei
    Chilamakuri, Chandra Sekhar Reddy
    Papachristou, Evangelia K.
    D'Santos, Clive
    Anand, Jayati
    Hinohara, Kunihiko
    Li, Wei
    McDonald, Thomas O.
    Luoma, Adrienne
    Modiste, Rebecca J.
    Quang-De Nguyen
    Michel, Brittany
    Cejas, Paloma
    Kadoch, Cigall
    Jaffe, Jacob D.
    Wucherpfennig, Kai W.
    Qi, Jun
    Liu, X. Shirley
    Long, Henry
    Brown, Myles
    Carroll, Jason S.
    Brugge, Joan S.
    Bradner, James
    Michor, Franziska
    Polyak, Kornelia
    MOLECULAR CELL, 2020, 78 (06) : 1096 - +
  • [7] MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
    Horiuchi, Dai
    Kusdra, Leonard
    Huskey, Noelle E.
    Chandriani, Sanjay
    Lenburg, Marc E.
    Gonzalez-Angulo, Ana Maria
    Creasman, Katelyn J.
    Bazarov, Alexey V.
    Smyth, James W.
    Davis, Sarah E.
    Yaswen, Paul
    Mills, Gordon B.
    Esserman, Laura J.
    Goga, Andrei
    JOURNAL OF EXPERIMENTAL MEDICINE, 2012, 209 (04): : 679 - 696
  • [8] The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality
    Papadimitriou, Marios
    Mountzios, Giannis
    Papadimitriou, Christos A.
    CANCER TREATMENT REVIEWS, 2018, 67 : 34 - 44
  • [9] Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer
    Rachel Brough
    Aditi Gulati
    Syed Haider
    Rahul Kumar
    James Campbell
    Erik Knudsen
    Stephen J. Pettitt
    Colm J. Ryan
    Christopher J. Lord
    Oncogene, 2018, 37 : 5701 - 5718
  • [10] Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer
    Brough, Rachel
    Gulati, Aditi
    Haider, Syed
    Kumar, Rahul
    Campbell, James
    Knudsen, Erik
    Pettitt, Stephen J.
    Ryan, Coim J.
    Lord, Christopher J.
    ONCOGENE, 2018, 37 (43) : 5701 - 5718
12345